Downloaded 26 times
More Related Content
Similar to Bowen predm cme.4.9.15
![latest in diabetes ppt 8.12.21 [Autosaved].ppt](https://cdn.slidesharecdn.com/ss_thumbnails/diabetesppt8-250113164357-608e4fb0-thumbnail.jpg?width=640&height=640&fit=bounds)
Bowen predm cme.4.9.15
- 1. Prediabetes: A Keyto Curbing the Diabetes Epidemic Michael E. Bowen, MD, MPH Assistant Professor Internal Medicine, Pediatrics, Clinical Sciences Divisions of General Internal Medicine, General Pediatrics, and Outcomes and Health Services Research Dedman Family Scholar in Clinical Care University of Texas Southwestern Medical Center, Dallas, TX
- 2. Disclosures Dr. Bowen hasno financial interests or other relationships with commercial concerns directly related to this program. Dr. Bowen will be discussing off-label uses of medications.
- 3. Objectives • Define prediabetes •Identify patients at risk for diabetes and prediabetes • Describe evidence-based treatments and interventions for prediabetes • Identify resources and develop strategies to improve the management of your patients with prediabetes
- 4. What is Prediabetes? •Glucose levels that are higher than normal, but not high enough to be diagnosed as diabetes – Umbrella term including impaired fasting glucose and impaired glucose tolerance • Precursor to diabetes – Asymptomatic condition diagnosed in the process of being tested for diabetes • “Risk factor” for diabetes vs. a clinical entity – Topic of vigorous debate – Bottom line • Diabetes risk increases across the glucose continuum • Prediabetes is a high-risk glucose state at increased risk for developing diabetes
- 5. Natural History ofType 2 Diabetes Figure courtesy of the AACE Diabetes Resource Center Fasting glucose Type 2 diabetes Years from diagnosis 0 5–10 –5 10 15 Prediabetes Onset Diagnosis Postprandial glucose Macrovascular complications Microvascular complications Insulin resistance Insulin secretion -Cell function
- 6. Summary: Hyperglycemia in Prediabetesand Diabetes • Hyperglycemia results from a combination of: –Beta-cell dysfunction Impaired insulin secretion –Increased hepatic glucose production due to excessive glucagon –Decreased uptake of peripheral glucose due to insulin resistance Diabetes Care. 2013; 36, Suppl 2:127-138.
- 7. Diagnosis Normal Impaired Fasting Glucose Diabetes Normal Impaired Glucose Tolerance Diabetes Normal Prediabetes Diabetes Fasting Glucose 2hour Glucose on OGTT Hemoglobin A1C 100 mg/dL 126 mg/dL 140 mg/dL 200 mg/dL 5.7% 6.5% Prediabetes • Agreement between tests is poor • 7.7% of population has Prediabetes by BOTH A1c and fasting glucose criteria • 4.9% have Prediabetes by A1c criteria alone • 20.5% have PDM by fasting glucose but not A1C • High variance in fasting glucose and 2 hour glucose values – confirm abnormal tests Diabetes Care. 2015;38 Suppl 1: S8-16. Diabetes Care. 2010;33 (10):2190-2195.
- 8. Diabetes is Justthe Tip of the Iceberg! NCDC and Prevention. National Diabetes Statistics Report, 2014. http://www.cdc.gov/diabetes/pubs/statsreport14/national-diabetes-report-web.pdf. MMWR Morbidity and Mortality Weekly Report. 2013;62:209-212. 29 Million with Type 2 Diabetes (9.3% of the Population) 86 Million with Prediabetes (37% of the Population) 77 Million of those with Prediabetes are UNDIANOSED
- 9. Change in USPrevalence: 2007-2010 0 20 40 60 80 100 120 140 2007 2012 57 86 17.9 29 5.7 8.1 People(Millions) Undiagnosed Diabetes Diagnosed Diabetes Prediabetes Diabetes:9.3% of Population Prediabetes:37% of Population CDC and Prevention. National diabetes fact sheet, 2007. http://www.cdc.gov/Diabetes/pubs/pdf/ndfs_2007.pdf. CDC and Prevention. National Diabetes Statistics Report, 2014. http://www.cdc.gov/diabetes/pubs/statsreport14/national-diabetes-report-web.pdf.
- 10. Projecting the FutureBurden of Diabetes 7.8 3.3 22.9 14.7 8.4 Estimated that 1 in 3 US adults will develop DM in their lifetime Boyle et al. Population Health Metrics 2010,8:29. 200-300% Increase in Prevalence (2010-2050)
- 11. Curbing the DiabetesEpidemic Non-modifiable Risk Factors • Age • Family history • Race/Ethnicity Modifiable Risk Factors • Overweight/obesity • Hypertension • Physical inactivity • Abnormal lipid metabolism • Prediabetes/elevated glucose levels • Recognition and Modification of Risk Factors • Diagnosis and treatment of Prediabetes Diabetes Care. 2014;37(suppl 1):S14-S80.
- 12. Case 1: Screening Mrs.D is a healthy, 44 year old nulliparous African American female presenting for an annual exam. Her BP is 129/76 and BMI is 26 kg/m2. She takes no medications and does yoga 2 days per week and attends a spinning class at the YMCA 3 days per week. She has no family history of diabetes. Her lipid panel from today’s visit is pending. Diabetes screening is recommended based on which of the following risk factors: A. Age B. BMI C. Physical inactivity D. Race E. Age and Race F. BMI and Race G. None of the above – screening is not indicated
- 13. Diabetes Screening Guidelines •American Diabetes Association (and revised USPSTF) – All adults over age 45 – BMI ≥ 25 (or ≥ 23 in Asians) and ANY of: • Non-white race Hypertension • HDL<35 or TG >250 Family history • PCOS Baby > 9# or gestational DM • Cardiovascular disease Physical inactivity • Prediabetes • Recommended Screening AND Diagnostic tests: – Hemoglobin A1C, Fasting glucose, Oral Glucose Tolerance Test • Repeat screening every 3 years if normal – Annually if prediabetes Diabetes Care. 2014;37(suppl 1):S14-S80.
- 14. Diabetes Screening • Proactivediabetes screening – Only 50% of eligible patients screened • Prediabetes is ONLY identified through diabetes screening – Improved diabetes screening is critical to: • Diabetes detection • Prediabetes detection • Diabetes prevention http://www.clinicalendocrinologynews.com/news/news/single-article/only-half-of-at-risk-adults-being-screened-for- diabetes/d23d462bfa6c020ddf93a82cd08c3d2e.html
- 15. Random Glucose asOpportunistic Screening? • Random glucose is routinely tested – 95% of glucose tests in clinical practice are random • Role for random glucose in screening is poorly defined • Diagnosis: Random glucose≥ 200 mg/dL in the setting of polyuria/polydipsia • What about random glucose values < 200mg/dL? Diabetes Care. 2004;27:9-12. Diabetes Care. 2014;37(suppl 1):S14-S80
- 16. Random Glucose asa Diabetes Risk Factor? Glucose Criteria Undiagnosed Pre-DM Undiagnosed DM Random Glucose≥100mg/dL 3.3 (3.0, 3.8) 31.2 (21.3, 45.5) RBG≥100mg/dL (Adjusted)* 2.4 (2.0, 2.7) 20.4 (14.0, 29.6) Results Stratified by Random Glucose Level Random glucose <100 mg/dL* Reference Reference Random glucose 100-119 mg/dL* 2.2 (1.9, 2.5) 7.1 (4.4, 11.4) Random glucose 120-139 mg/dL* 3.29 (2.6, 4.2) 30.3 (20.0, 46.0) Random glucose ≥140 mg/dL* 3.5 (2.2, 5.5) 256.0 (150.0, 436.9) Results presented as weighted odds ratios *Adjusted for age, sex, race, BMI, HTN, HLD, CVD, FH Diabetes J Clin Endocrinol Metab. 2015; http://press.endocrine.org/doi/abs/10.1210/jc.2014-4116
- 17. Case 1: Screening Mrs.D is a healthy, 44 year old nulliparous African American female presenting for an annual exam. Her BP is 129/76 and BMI is 26 kg/m2. She takes no medications and does yoga 2 days per week and attends a spinning class at the YMCA 3 days per week. She has no family history of diabetes. Her lipid panel from today’s visit is pending. Diabetes screening is recommended based on which of the following risk factors: A. Age B. BMI C. Physical inactivity D. Race E. Age and Race F. BMI and Race G. None of the above – screening is not indicated
- 18. Risks Associated withPrediabetes • Increased risk for diabetes1,2 – Approximately 25% develop diabetes over 3-5 years • Increased risk of cardiovascular disease1,2,3,4 • Increased risk of chronic kidney disease2,4 • Increased risk of neuropathy2,4 • Increased risk of Retinopathy1,2 • Increased risk of cancer5 – Liver, endometrial, stomach, colorectal 1Diabetes Care; 2007; (39(3). 753-759 2Endocrine Practice. 2008; 14(7):933-946. 3N Engl J Med.2010; 362(9): 800-811. 4J Am Coll Cardiol. 2012; 59: 635-643. 5Diabetologia. 2014; 57(11): 2261-2269.
- 19. What is theEvidence? LIFESTYLE MODIFICATION AND DIABETES PREVENTION
- 20. Case 2: PrediabetesTreatment Mrs. K, a 46 year old Hispanic female with a BMI of 29 kg/m2, was recently diagnosed with prediabetes (fasting glucose 109 mg/dL and A1C 6.1%). Which of the following evidence based interventions should you recommend? A. Metformin B. Lifestyle intervention with goal 7% weight loss C. Acarbose D. Orlistat E. Metformin + Lifestyle
- 21. Diabetes Prevention Program(DPP) • 1996-1999: randomized controlled trial • Multicenter trial (n=27) that enrolled 3,234 patients without DM – BMI ≥ 24 kg/m2 (≥ 22 kg/m2 in Asians) – Fasting plasma glucose 95-125 mg/dL or 2H post prandial glucose 140-199 mg/dL • Randomized to: – Standard lifestyle + placebo – Standard lifestyle + metformin (started 850mg QD; increase to 850mg BID at 1 month) – Intensive lifestyle intervention • Primary outcome: Diabetes (diagnosed by annual OGTT or twice yearly fasting plasma glucose) – Mean Followup: 2.8 years N Engl J Med. 2002;346:393-403.
- 22. DPP: Lifestyle Intervention •Intensive intervention – Goal 7% weight loss • 25% of calories from fat • 1200-1800 kcal/day goal based on initial body weight – >150 minutes of physical activity each week • Intensity target: brisk walking • At least 700 kcal/week – Individualized, one-on-one 16 lesson curriculum over 24 weeks • Monthly individual and group sessions to reinforce changes N Engl J Med. 2002;346:393-403.
- 23. DPP: Baseline Demographics CharacteristicDPP Study Population (N=3234) Age, year (SD) 50.6 (10.7) Female sex, % 67.7 Race White, % 54.7 African American, % 19.9 Hispanic, % 15.7 Asian, % 4 Family History of diabetes, % 69.4 BMI 34 (6.7) Fasting plasma glucose 106.5 (8.3) 2 hour glucose (OGTT) 164.6 (17.0) A1C, % 5.91 (0.50)
- 24. DPP: Diabetes Incidence StudyArm Crude DM Incidence/100 person years Relative Risk Reduction Placebo 11% Reference Metformin 7.8%* 31% (17-43) Lifestyle Intervention 4.8%* 58% (48-66) *P<0.001 vs. placebo N Engl J Med. 2002;346:393-403. Circulation: Cardiovascular Quality and Outcomes.i 2009;2:279-285. DynaMed Weekly Update. 2014; 8(47). Study Arm Cumulative DM Incidence at 3 y Number Needed to Treat (3 years) Placebo 28.9% ---- Metformin 21.7% 13.9 (5.4-9.5) Lifestyle Intervention 14.4% 6.9 (5.4-9.5) Statins: Primary CAD Prevention: 5-year NNT = 108 assuming 7.5% 10-year baseline risk Aspirin: Primary CAD Prevention: 5-year NNT > 300
- 25. DPP: Goal Attainmentin the Lifestyle Intervention At 24 weeks At End of Study Weight loss > 7% 50% 38% Exercise > 150 minutes/week 74% 58% N Engl J Med. 2002;346:393-403. 2Diabetes Care. 2006; 29.2012-2017. • For every 1 kg in weight loss, a 16% reduction in diabetes risk over 3 years2 • Adjusted for changes in diet and activity
- 26. Changes in Weight,Activity, and Med Adherence Mean Weight Loss Placebo: 0.1 kg Metformin: 2.1 kg Lifestyle: 5.6 kg N Engl J Med. 2002;346:393-403.
- 27. DPP: Subgroup Analyses •Subgroup analyses, underpowered – Age, sex, race, BMI, fasting and 2H glucose levels • Lifestyle Intervention – effective in all subgroups – More effective if lower 2 hour OGTT glucose • Metformin – More effective at BMI ≥ 35 kg/m2 – Fasting glucose 110-125 mg/dL N Engl J Med. 2002;346:393-403.
- 28. Lifestyle Modification andDM Prevention – Additional Trials Study N Intervention Primary Outcome: Relative Risk Reduction DPP (2002)1 3324 Diet+Exercise 58% at 2 years Finnish DPS (2001)2 522 Diet+Exercise 58% at 3 years Da Qing (1997)3, 4 577 Diet/Exercise/Diet+Exercise 51% at 6 years Indian DPP (2006)5 531 Diet+exercise 28.5% at 2.5 years 1N Engl J Med. 2002;346:393-403. 2N Engl J Med. 2001;344:1343-1350. 3 Lancet.2008;371:1783-1789. 4Diabetes Care. 1997;20:537-544. 5Diabetologia. 2006;49(2):289-297.
- 29. Case 2: PrediabetesTreatment Mrs. K, a 46 year old Hispanic female with a BMI of 29 kg/m2, was recently diagnosed with prediabetes (fasting glucose 109 mg/dL and A1C 6.1%). Which of the following evidence based interventions should you recommend? A. Metformin B. Lifestyle intervention with goal 7% weight loss C. Acarbose D. Orlistat E. Metformin + Lifestyle
- 30. Case 3: LongTerm Treatment Effects You recommended lifestyle modification with at least a 7% weight loss goal for Mrs. K based on the findings from the DPP. At 1 year, she successfully loses 6% of her body weight and has a fasting glucose of 95 mg/dL and an A1C of 5.7%. Twelve months later she has regained 10 pounds and has a fasting glucose of 109 mg/dL and an A1C of 6.0%. What is her 10 year risk of developing diabetes? A. Unchanged compared to baseline risk B. Lower risk by virtue of reverting to normal glycemia over the past year C. Higher risk because she has shown she cannot sustain her weight loss goals
- 31. Diabetes Prevention: LongTerm Impact of Lifestyle Intervention? Study N Intervention Followup Relative Risk Reduction DPP (2002)1 3324 Diet+Exercise 10 years 24% Finnish DPS (2001)2 522 Diet+Exercise 7 years 43% Da Qing (1997)3 577 Diet+Exercise 20 years 43% 1Lancet. 2009;374:1677-1686. 2Lancet. 2006;368(9548):1673-1679. 3 Lancet.2008;371:1783-1789. 4Lancet. 2012;379:2243-2251. • DPP4 – Participants going from prediabetes to normal glucose regulation at least once during the study had a 56% lower risk of diabetes over 10 years — Reversion to normal glucose tolerance associated with younger age, weight loss, intensive lifestyle intervention
- 32. Case 3: LongTerm Treatment Effects You recommended lifestyle modification with at least a 7% weight loss goal for Mrs. K based on the findings from the DPP. At 1 year, she successfully loses 6% of her body weight and has a fasting glucose of 95 mg/dL and an A1C of 5.7%. Twelve months later she has regained 10 pounds and has a fasting glucose of 109 mg/dL and an A1C of 6.0%. What is her 10 year risk of developing diabetes? A. Unchanged compared to baseline risk B. Lower risk by virtue of reverting to normal glycemia over the past year C. Higher risk because she has shown she cannot sustain her weight loss goals
- 33. What is theEvidence? PHARMACOLOGIC TREATMENT AND DIABETES PREVENTION
- 34. Case 4: Medicationsfor Prediabetes Mr. R is a 58 year old Caucasian male with a history of coronary artery disease. He is overweight (BMI 37 kg/m2), a smoker, and has hypertension and high cholesterol. He has severe peripheral vascular disease that limits his exercise. His fasting glucose is 117 mg/dL and his A1C is 6.3%. Which of the following medications is FDA approved to treat his prediabetes? A. Metformin B. Acarbose C. Pioglitazone D. Orlistat E. All of the above F. None of the above
- 35. Medication RCTs forDiabetes Prevention Study N Duration Medication Dose/day Relative Risk Reduction Side Effects DPP1 3324 3 y Metformin 1700mg 31% GI IDPP2 531 2.5 y Metformin 500mg 26% GI Stop NIDDM3 1429 3 y Acarbose 300mg 25% GI ACT NOW4 602 2 y Pioglitazone 45mg 72% Weight gain, edema DREAM5 5269 3 y Rosiglitazone 8 mg 60% CHF, weight gain CANOE6 207 4 y Rosiglitazone + Metformin 4mg 1000 mg 66% diarrhea 1N Engl J Med. 2002;346:393-403 2Diabetologia. 2006;49(2):289-297 3Lancet. 2002;359(9323):2072-2077. 4N Engl J Med. 2011;346:1104-1115. 5Lancet. 2006;368(9541):1096-1105. 6Lancet. 2010;376(9735):103-111.
- 36. Cardiovascular and LongTerm Outcomes with Medications • Acarbose (STOP-NIDDM Trial) may improve cardiovascular outcomes1 – 49% relative reduction (2.5% absolute risk reduction) in CV events – Caveat: Study powered for diabetes incidence, not CVD (Only 84 events) • 1.4% per year (placebo) vs. 0.7% per year (Acarbose) 1JAMA. 2003;290(4):486-494
- 37. What is theDurability of Medication Effects for Diabetes prevention? • Most medications effects do no persist after discontinued • Metformin is exception: 25% reduction after 2-week washout period2 • Relevance of this is unclear 1JAMA. 2003;290(4):486-494. 2Diabetes Care. 2003;6:977-980.
- 38. Weight loss Medicationsand Diabetes Prevention • No adequately powered RCTs examining weight loss drugs and diabetes prevention • Eligibility for weight loss medication1 – Failed weight loss goals by lifestyle alone – BMI ≥ 30 kg/m2 or ≥ 27 kg/m2 with weight related complications – Not pregnant, seeking pregnancy, nursing 1Obesity. 2013;22:S5-S39.
- 39. Weight Loss Medicationsand Diabetes Prevention • Orlistat – lipase inhibitor – XENDOS1 – 4 year double blind placebo-controlled RCT powered to detect progression to diabetes – Lifestyle + Orlistat 120mg TID vs. Lifestyle + placebo • Included subjects with BMI≥30 kg/m2 and normal (79%) or IGT (21%) • 52% completion rate – 36% risk reduction for incident diabetes (p=0.003) • Underpowered to examine conversion from preDM to DM • Phentermine/Topiramate ER (Qsymia) – Subgroup analysis of Phase 3 Trial – underpowered – Phentermine/Topiramate ER vs. Placebo – 7.5 mg/46mg dose: 49% risk reduction – 15mg/92mg dose: 89% risk reduction – Greater weight loss, greater reduction in diabetes incidence • greatest benefit ≥15% weight loss 1Diabetes Care. 2004;27:155-161. 2Diabetes Care. 2014;37:912-921
- 40. Medications for DiabetesPrevention: Summary • No medications are currently FDA approved for treatment of prediabetes or diabetes prevention • Thiazolidinediones – concerns about long term cardiovascular safety • Acarbose – safe, but up to 40% discontinuation for GI side effects • Orlistat – Safe, but use limited by GI side effects (up to 90% of patients have GI side effects) Diabetes Care 2015;38(Suppl1)S313-32.
- 41. Metformin – OffLabel Recommendations in Prediabetes • Recommendations based on the safety, tolerability, and efficacy relative to other medication options • American Diabetes Association – BMI > 35 kg/m2 – Age < 60 – Prior gestational diabetes Diabetes Care 2015;38(Suppl1)S313-32.
- 42. Summary: Prediabetes Treatment •Lifestyle modification – Goal 5-10% weight loss – Moderate intensity physical activity (approximately 30 minutes per day or 150 minutes per week) • Metformin – Off label use based on Diabetes Prevention Program findings • Age < 60 • BMI > 35 kg/m2 • Prior gestational diabetes
- 43. Case 4: Medicationsfor Prediabetes Mr. R is a 58 year old Caucasian male with a history of coronary artery disease. He is overweight (BMI 37 kg/m2), a smoker, and has hypertension and high cholesterol. He has severe peripheral vascular disease that limits his exercise. His fasting glucose is 117 mg/dL and his A1C is 6.3%. Which of the following medications is FDA approved to treat his prediabetes? A. Metformin B. Acarbose C. Pioglitazone D. Orlistat E. All of the above F. None of the above
- 44. Translating Evidence intoPractice
- 45. Setting Goals withYour Patients • Goals should be set by patients – Nutrition/dietary goal – Physical activity goal • Partner with – Nutritionists – Wellness Coaches • Healthcare team – Discuss goals with patient – Facilitate success – Provide support • S – Specific Simple and clear • M – Measurable Key to reaching goal • A – Attainable Pick goals you can reach • R – Relevant Pick goals important to you • T – Timely Beginning and end
- 46. Characteristics of SuccessfulLifestyle Intervention Programs • Intensive: small group or one-on-one for 6 –12 months • Extended: > 2 years contact duration • Multi-component – Reduced total caloric intake, reduced fat intake – Exercise – Increased fiber intake • Well integrated behavioral principles • Moderate weight loss: – 5-7% weight loss – 3-4% long-term weight loss maintenance
- 47. Implementing the DPPLifestyle Intervention in the Community • DEPLOY (Diabetes Education & Prevention with a Lifestyle Intervention Offered at the YMCA – Pilot Study at 2 YMCAs • Randomized 92 participants • Group Lifestyle vs. control (brief counseling) – Eligibility: • BMI ≥ 24 kg/m2 and ≥ 2 diabetes risk factors • Random capillary glucose 110-199 mg/dL Am J Prev Med. 2008;35:357-363.
- 48. DEPLOY: Outcomes • Outcomeat 4-6 months Am J Prev Med. 2008;35:357-363. Outcome Control (n=38) Intervention (n=38) P value % weight loss -2% (-3.3, -0.6) -6% (-7.3, -4.7) <0.001 % BMI decrease -2.3% (-3.7, -0.8) -5.8% (-7.3, -4.4) 0.001 Change in Total Cholesterol +6 mg/dL (-2.8, 14.8) -21.6 mg/dL (-29.2, -13.3) <0.001 • Effects sustained after 12 months • No differences by race and gender
- 49. YMCA Diabetes PreventionProgram • Community-based study based on DPP lifestyle intervention – Offered at 7 DFW YMCAs • 12 month program – 16 one-hour weekly sessions – Monthly small group session with lifestyle coach • Program Goals – Lose 7% body weight – Goal 150 minutes/week physical activity http://www.ymcadallas.org/healthy_living/health_well-being__fitness/diabetes_prevention/
- 50. “Prevent Diabetes STAT” •CDC and AMA initiative – Free toolkit to guide screening and referral – Fact sheets – Risk assessment tools – Referral letters – In-clinic flow process to identify high risk patients – Logic for EMR query to identify at risk patients • Online risk assessment for patients http://www.ama-assn.org/sub/prevent-diabetes-stat/index.html
- 51. Diabetes Prevention andthe ACA • ACA eliminated out of pocket fees for preventative services (New commercial/individual health plans (September 23, 2010) • Covers USPSTF “A” or “B” rated recommendations • INCLUDES: – Diabetes screening (Currently only for adults with hypertension) – Obesity screening – Nutrition counseling for those at high risk for chronic disease such as diabetes and hypertension http://intermountainhealthcare.org/ext/Dcmnt?ncid=522452203
- 52. ACA Coverage Service ServiceCodes ICD-9 Code Commercial and Private Insurance Individual Diet/exercise counseling 99401-99404 278.X (Obesity) 250.X (Diabetes) V65.3 (Dietary Counseling) V65.41 (Exercise Counseling) Medical Nutrition Therapy (dietician) 97802-97804 Varies by plan Medicare Plans Intensive Behavioral Therapy for Obesity Month 1: 1 visit/week Month 2-6: 1 biweekly visit Month 7-12: monthly visit only if lose ≥ 3kg at month 6 G0447 V85.30 to V85.39 Medical Nutrition Therapy (dietician) 97082-97084 Only if diabetes, renal disease, or renal transplant past 3 years Bariatric Surgery Covered if BMI>35 and at least 1 obesity-related comorbidity if previously unsuccessful with medical obesity treatment. http://intermountainhealthcare.org/ext/Dcmnt?ncid=522452203
- 53. Conclusions • Prediabetes isa strong but modifiable risk factor for developing diabetes • Early diagnosis and intervention is critical • Lifestyle modification is the cornerstone of prediabetes treatment • Insurance coverage is increasingly available for lifestyle modification and behavioral interventions
- 54.
- 55. Prediabetes: Historical Perspective •1950s: Retrospective diagnosis in pregnancy – Associated with High birthweight baby family history of diabetes • 1980s: WHO abolished concept – Many with borderline glucose do not convert to diabetes – ‘prediabetic’ label created issues in insurance coverage and ‘false alarm’ • 2002: ADA endorsement of prediabetes term leads to widespread use of the term Diabetes, Obesity, and Metabolism. 9(Suppl. 1.)2007. 12-18.
- 56. Statins and DiabetesRisk • Mild increase in diabetes incidence – 9% increased risk for incident diabetes1 • Treatment of 255 (95% CI 150-852) patients with statins for 4 years results in 1 case of diabetes • High-potency statins may increase risk for diabetes more than lower potency statins2 – 15% (95% CI 5-26%) increased risk in first 2 years after statin use for Rosuvastatin/Atorvastatin/Simvastatin (dose > 40mg) compared with all other statins • Retrospective study of patients hospitalized for new CV event • FDA3 – – “A small increased risk of raised blood sugar levels and the development of Type 2 diabetes have been reported for the use of statins.” – “…we think the heart benefit of statins outweighs this small increased risk….but blood sugar levels may need to be assessed after instituting statin therapy.” 1Lancet. 2010; 375(9716): 735-742 2BMJ. 2014; 348:g3244. 3www.fda.gov/ForConsumers/ConsumerUpdates/ucm293330.htm
- 57. Antihypertensives and DiabetesRisk • Thiazides- – RR 0.91 ( 95% CI 0.73-1.13) for incident diabetes compared with those on no antihypertensive therapy • Beta Blockers – RR 1.28 (95% CI 1.04-1.57) for incident diabetes compared with those on no antihypertensives • No increase in risk with ACE Inhibitors and Calcium Channel Blockers N Engl J Med. 2000;342:905-912.
- 58. DPP • Estimated numberneeded to treat over 3 years to prevent 1 case of diabetes • Lifestyle intervention: 6.9 (95% CI: 5.4-9.5) • Metformin: 13.9 (95% CI: 8.7-33.9) • Adverse Events • No treatment related deaths; no increase in hospitalizations • Gastrointestinal: Metformin (77.8) vs. Placebo (30.7) events per 100 person years • Musculoskeletal: Lifestyle (24.1) vs. Placebo (21.1) events per 100 person years
Editor's Notes
- #17 NHANES Analysis of patients without known diabetes. What is the association between a single random glucose value and risk for diabetes? TOP: for undiagnosed preDM – unadjusted OR of 3.3 is more strongly associated with any diabetes risk factor other than age. For undiagnosed DM – a single RBG >=100 is more strongly associated with undiagnosed DM than any single DM risk factor – even after adjustment for other risk factors.
- #27 In the Lifestyle Group: 50% achieved the target ≥weight loss at 24 weeks; 38% met target at last study visit 74% met physical activity goal (>150min activity per week) at 24 weeks; and 58% at most recent week
- #31 NOTE – make % and weights consistent here
- #33 NOTE – make % and weights consistent here
- #40 Phentermine/Topiramate; Noradrenergic + GABA-receptor activator
- #50 Per YMCA website: ages 18+; cost $180 for full member; $250 for nonmember; ?some insurance coverage – United Health